Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia
Summary: Fibromyalgia (FM) is a complex, chronic, nondegenerative musculoskeletal disorder of unknown etiology, and it requires a different clinical approach for every patient. Objectives: The present clinical follow-up observes the effect of the central-acting myorelaxant thiocolchicoside...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2025-01-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/117694/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582835334021120 |
|---|---|
| author | Valentina Reshkova Simeon Monov Alexander Mandadjiev |
| author_facet | Valentina Reshkova Simeon Monov Alexander Mandadjiev |
| author_sort | Valentina Reshkova |
| collection | DOAJ |
| description | Summary: Fibromyalgia (FM) is a complex, chronic, nondegenerative musculoskeletal disorder of unknown etiology, and it requires a different clinical approach for every patient. Objectives: The present clinical follow-up observes the effect of the central-acting myorelaxant thiocolchicoside (Tiyozid®) on clinical manifestations in patients with primary fibromyalgia. Methods: The following article presents a prospective clinical follow-up in eighteen ambulatory women with primary fibromyalgia observed in 41 days. Results: A significant difference between the 1st and 41st day of treatment with thiocolchicoside (Tiyozid®) 4 mg tablets in the mean number of pain points (15.4 ± 1.9 vs. 13.17 ± 1.5, p < 0.05), an increase in pain threshold (2.37 ± 0.4 to 2.58 ± 0.3, p > 0.05), and a decrease in the degree of chronic fatigue (7.1 ± 0.8 vs. 3.5 ± 1.3, p < 0.05). On the 41st day, the overall impact of treatment with thiocolchicoside on quality of life showed a significant improvement (37.5 ± 11 vs. 28 ± 8, p < 0.05). Conclusion: As a short-term therapy, thiocolchicoside (Tiyozid®) has a positive effect on clinical manifestations in patients with primary fibromyalgia, which affects everyday activities and improves their quality of life. |
| format | Article |
| id | doaj-art-d8e8275ba30f4faf8430a41c993ea5fc |
| institution | Kabale University |
| issn | 2603-557X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Pharmacia |
| spelling | doaj-art-d8e8275ba30f4faf8430a41c993ea5fc2025-01-29T08:30:52ZengPensoft PublishersPharmacia2603-557X2025-01-01721810.3897/pharmacia.72.e117694117694Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgiaValentina Reshkova0Simeon Monov1Alexander Mandadjiev2“St. Ivan Rilski” University Hospital“St. Anna” University HospitalNobel Pharma BulgariaSummary: Fibromyalgia (FM) is a complex, chronic, nondegenerative musculoskeletal disorder of unknown etiology, and it requires a different clinical approach for every patient. Objectives: The present clinical follow-up observes the effect of the central-acting myorelaxant thiocolchicoside (Tiyozid®) on clinical manifestations in patients with primary fibromyalgia. Methods: The following article presents a prospective clinical follow-up in eighteen ambulatory women with primary fibromyalgia observed in 41 days. Results: A significant difference between the 1st and 41st day of treatment with thiocolchicoside (Tiyozid®) 4 mg tablets in the mean number of pain points (15.4 ± 1.9 vs. 13.17 ± 1.5, p < 0.05), an increase in pain threshold (2.37 ± 0.4 to 2.58 ± 0.3, p > 0.05), and a decrease in the degree of chronic fatigue (7.1 ± 0.8 vs. 3.5 ± 1.3, p < 0.05). On the 41st day, the overall impact of treatment with thiocolchicoside on quality of life showed a significant improvement (37.5 ± 11 vs. 28 ± 8, p < 0.05). Conclusion: As a short-term therapy, thiocolchicoside (Tiyozid®) has a positive effect on clinical manifestations in patients with primary fibromyalgia, which affects everyday activities and improves their quality of life.https://pharmacia.pensoft.net/article/117694/download/pdf/ |
| spellingShingle | Valentina Reshkova Simeon Monov Alexander Mandadjiev Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia Pharmacia |
| title | Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia |
| title_full | Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia |
| title_fullStr | Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia |
| title_full_unstemmed | Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia |
| title_short | Off-label short-term use of thiocolchicoside (Tiyozid®) in the clinical therapy of fibromyalgia |
| title_sort | off label short term use of thiocolchicoside tiyozid r in the clinical therapy of fibromyalgia |
| url | https://pharmacia.pensoft.net/article/117694/download/pdf/ |
| work_keys_str_mv | AT valentinareshkova offlabelshorttermuseofthiocolchicosidetiyozidintheclinicaltherapyoffibromyalgia AT simeonmonov offlabelshorttermuseofthiocolchicosidetiyozidintheclinicaltherapyoffibromyalgia AT alexandermandadjiev offlabelshorttermuseofthiocolchicosidetiyozidintheclinicaltherapyoffibromyalgia |